secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-042870
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar Biosciences to explore strategic alternatives; hires Oppenheimer as advisor
--------------------------------------------------------------------------------

- Board authorized exploration of M&A, partnerships, licensing or other transactions; no deal reached.
- Oppenheimer & Co. retained as exclusive financial advisor for the strategic evaluation process.
- CEO James Caruso cites need for a partner to develop lead asset iopofosine I-131 and pipeline.
- Alpha- and Auger-emitting radioconjugates CLR 225 and CLR 125 in solid tumors are additional opportunities.
- No timetable set; company will not update progress unless a definitive agreement is reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925042870/0001104659-25-042870-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465925042870/tm2513754d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-042870

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer